Find Momelotinib Hydrochloride manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

VMF

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

0

Australia

0

South Africa

0

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Momelotinib dihydrochloride monohydrate, Ldx8893l5d, Cyt-387 dihydrochloride monohydrate, Cyt-11387 dihydrochloride monohydrate, Momelotinib hydrochloride hydrate (jan), Momelotinib hydrochloride hydrate [jan]
Molecular Formula
C23H26Cl2N6O3
Molecular Weight
505.4  g/mol
InChI Key
RQKCPSIFARJBOR-UHFFFAOYSA-N
FDA UNII
LDX8893L5D

Momelotinib Hydrochloride
Momelotinib Dihydrochloride Monohydrate is the monohydrate dihydrochloride salt form of momelotinib, an orally bioavailable small molecule inhibitor of wild-type (WT) Janus kinases 1 and 2 (JAK1/2), the JAK2 mutant form JAK2V617F, and activin A receptor type 1 (ACVR1; activin receptor like kinase 2; ALK2), with antineoplastic activity. Upon oral administration, momelotinib competes with JAK1/2 for ATP binding, which results in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and leads to the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells. In addition, the inhibition of ALK2 prevents liver hepcidin formation, increases iron availability and increases red blood cell (RBC) production. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.
1 2D Structure

Momelotinib Hydrochloride

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide;hydrate;dihydrochloride
2.1.2 InChI
InChI=1S/C23H22N6O2.2ClH.H2O/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29;;;/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28);2*1H;1H2
2.1.3 InChI Key
RQKCPSIFARJBOR-UHFFFAOYSA-N
2.2 Other Identifiers
2.2.1 UNII
LDX8893L5D
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. Momelotinib Dihydrochloride Monohydrate

2. Ldx8893l5d

3. Cyt-387 Dihydrochloride Monohydrate

4. Cyt-11387 Dihydrochloride Monohydrate

5. Momelotinib Hydrochloride Hydrate (jan)

6. Momelotinib Hydrochloride Hydrate [jan]

7. Benzamide, N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)-, Hydrochloride, Hydrate (1:2:1)

8. Benzamide, N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-, Hydrochloride, Hydrate (1:2:1)

9. N-(cyanomethyl)-4-(2-(4-(morpholin-4-yl)anilino)pyrimidin-4-yl)benzamide Dihydrochloride Monohydrate

10. N-(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide Dihydrochloride Monohydrate

11. Unii-ldx8893l5d

12. Ojjaara

13. 1841094-17-4

14. Ojjaara (tn)

15. Omjjara (tn)

16. Schembl17333087

17. D10889

2.4 Create Date
2015-12-28
3 Chemical and Physical Properties
Molecular Weight 505.4 g/mol
Molecular Formula C23H26Cl2N6O3
Hydrogen Bond Donor Count5
Hydrogen Bond Acceptor Count8
Rotatable Bond Count6
Exact Mass Da
Monoisotopic Mass Da
Topological Polar Surface Area104
Heavy Atom Count34
Formal Charge0
Complexity615
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count4

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1841094-17-4 / Momelotinib Hydrochloride API manufacturers, exporters & distributors?

Momelotinib Hydrochloride manufacturers, exporters & distributors 1

43

PharmaCompass offers a list of Momelotinib Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Momelotinib Hydrochloride manufacturer or Momelotinib Hydrochloride supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Momelotinib Hydrochloride manufacturer or Momelotinib Hydrochloride supplier.

API | Excipient name

Momelotinib Hydrochloride

Synonyms

Momelotinib dihydrochloride monohydrate, Ldx8893l5d, Cyt-387 dihydrochloride monohydrate, Cyt-11387 dihydrochloride monohydrate, Momelotinib hydrochloride hydrate (jan), Momelotinib hydrochloride hydrate [jan]

Cas Number

1841094-17-4

Unique Ingredient Identifier (UNII)

LDX8893L5D

About Momelotinib Hydrochloride

Momelotinib Dihydrochloride Monohydrate is the monohydrate dihydrochloride salt form of momelotinib, an orally bioavailable small molecule inhibitor of wild-type (WT) Janus kinases 1 and 2 (JAK1/2), the JAK2 mutant form JAK2V617F, and activin A receptor type 1 (ACVR1; activin receptor like kinase 2; ALK2), with antineoplastic activity. Upon oral administration, momelotinib competes with JAK1/2 for ATP binding, which results in inhibition of JAK1/2 activation, inhibition of the JAK-STAT signaling pathway, and leads to the induction of apoptosis and a reduction of tumor cell proliferation in JAK1/2-expressing tumor cells. In addition, the inhibition of ALK2 prevents liver hepcidin formation, increases iron availability and increases red blood cell (RBC) production. JAK2 is the most common mutated gene in bcr-abl-negative myeloproliferative disorders; the JAK2V617F gain-of-function mutation involves a valine-to-phenylalanine modification at position 617. The JAK-STAT signaling pathway is a major mediator of cytokine activity and is often dysregulated in a variety of tumor cell types.

Momelotinib Hydrochloride Manufacturers

A Momelotinib Hydrochloride manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Momelotinib Hydrochloride, including repackagers and relabelers. The FDA regulates Momelotinib Hydrochloride manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Momelotinib Hydrochloride API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Momelotinib Hydrochloride manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Momelotinib Hydrochloride Suppliers

A Momelotinib Hydrochloride supplier is an individual or a company that provides Momelotinib Hydrochloride active pharmaceutical ingredient (API) or Momelotinib Hydrochloride finished formulations upon request. The Momelotinib Hydrochloride suppliers may include Momelotinib Hydrochloride API manufacturers, exporters, distributors and traders.

click here to find a list of Momelotinib Hydrochloride suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Momelotinib Hydrochloride NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Momelotinib Hydrochloride as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Momelotinib Hydrochloride API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Momelotinib Hydrochloride as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Momelotinib Hydrochloride and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Momelotinib Hydrochloride NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Momelotinib Hydrochloride suppliers with NDC on PharmaCompass.

Momelotinib Hydrochloride GMP

Momelotinib Hydrochloride Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Momelotinib Hydrochloride GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Momelotinib Hydrochloride GMP manufacturer or Momelotinib Hydrochloride GMP API supplier for your needs.

Momelotinib Hydrochloride CoA

A Momelotinib Hydrochloride CoA (Certificate of Analysis) is a formal document that attests to Momelotinib Hydrochloride's compliance with Momelotinib Hydrochloride specifications and serves as a tool for batch-level quality control.

Momelotinib Hydrochloride CoA mostly includes findings from lab analyses of a specific batch. For each Momelotinib Hydrochloride CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Momelotinib Hydrochloride may be tested according to a variety of international standards, such as European Pharmacopoeia (Momelotinib Hydrochloride EP), Momelotinib Hydrochloride JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Momelotinib Hydrochloride USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty